Document is current
Any future updates will be listed below
-
Authors
van Sabben, Joris M. https://orcid.org/0009-0007-7079-1193
van der Kleij, Maud B. A.
Roets, Evelyne
Tissier, Renaud L. M.
van Balen, Dorieke E. M.
Huitema, Alwin D. R.
Desar, Ingrid M. E.
Reyners, Anna K. L.
Gelderblom, Hans
Steeghs, Neeltje
- License Information
-
More Information
Article History
Received: 23 April 2025
Accepted: 28 May 2025
First Online: 1 July 2025
Declarations
:
: Neeltje Steeghs provided consultation or attended advisory boards for Boehringer Ingelheim, Bristol-Myers Squibb, Ellipses Pharma, GlaxoSmithKline, and Incyte. N. Steeghs received research grants from Abbvie, Actuate Therapeutics, Amgen, Anaveon, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, CellCentric, Cogent Biosciences, Cresecendo Biologics, Daiichi Sankyo, Deciphera, Exelixis, Genentech, GlaxoSmithKline, Iambic, IDRx, Immunocore, Incyte, Janssen, Kling Biotherapeutics, Lixte, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Pfizer, Revolution Medicin, Roche, Sanofi, and Zentalis—all outside the submitted work, with all payment to the Netherlands Cancer Institute. Joris van Sabben, Maud van der Kleij, Evelyne Roets, Renaud Tissier, Dorieke van Balen, Alwin Huitema, Ingrid Desar, Anna Reyners and Hans Gelderblom declare no conflicts of interest.
: The study received approval from the Internal Review Board of the Netherlands Cancer Institute (IRBd24-086) and was conducted in accordance with the principles outlined in the Declaration of Helsinki. All patients provided written informed consent for retrospective use of their data for research purposes.
